Literature DB >> 7648675

VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat.

D Zahger1, M C Fishbein, L I Garfinkel, P K Shah, J S Forrester, J Regnstrom, J Yano, B Cercek.   

Abstract

BACKGROUND: Arterial injury is immediately followed by platelet adhesion at the site of injury, a process that requires the interaction of subendothelial von Willebrand factor with the platelet GP1b receptor. VCL, a recombinant von Willebrand factor GP1b binding domain, inhibits platelet binding to von Willebrand factor. The aim of this study was to determine whether VCL inhibits platelet adhesion at the site of arterial injury and affects neointimal thickening after injury in rats. METHODS AND
RESULTS: Sprague-Dawley rats were randomized to receive VCL, 4 mg/kg bolus followed by a continuous infusion of 2 mg.kg-1.h-1 for 72 hours, or an identical volume of saline. Balloon injury of the femoral artery was performed 15 minutes after the initial bolus injection of VCL. Scanning electron microscopy performed 1 and 3 days after injury indicated that VCL-treated rats had > 80% reduction in the number of platelets adherent to the vessel wall at the site of injury compared with controls (P < .003). Histological examination at day 14 showed that, compared with controls, VCL-treated rats had a 60% reduction in the intima-media ratio (0.21 +/- 0.03 versus 0.53 +/- 0.06, P = .001) and a reduced luminal area stenosis (12 +/- 3% versus 38 +/- 10%, P = .04). At 28 days after injury, there was no rebound of neointimal thickening in VCL-treated rats (intima-media ratio, 0.19 +/- 0.04; luminal stenosis, 17 +/- 5%). The difference between VCL-treated rats and control rats persisted but was attenuated (intima-media ratio, 0.19 +/- 0.04 versus 0.28 +/- 0.1, P = .162; luminal stenosis, 17 +/- 5% versus 31 +/- 5%, P = .058) as neointimal thickening regressed in untreated rats. With the use of proliferating cell nuclear antigen immunohistochemistry on day 3, VCL had no effect on smooth muscle cell (SMC) proliferation.
CONCLUSIONS: Antagonism of the platelet GP1b receptor by VCL profoundly decreased platelet deposition at the site of balloon injury in the rat femoral artery. This effect was associated with a persistent reduction in neointimal thickening. The lack of effect of VCL on SMC proliferation suggests that the decrease in neointimal thickening may have been mediated through inhibition of SMC migration and/or modulation of the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648675     DOI: 10.1161/01.cir.92.5.1269

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  Role of platelet adhesion in homeostasis and immunopathology.

Authors:  D N Männel; G E Grau
Journal:  Mol Pathol       Date:  1997-08

Review 2.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

3.  Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.

Authors:  Junling Liu; Malinda E Fitzgerald; Michael C Berndt; Carl W Jackson; T Kent Gartner
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

Review 4.  The mechanisms of coronary restenosis: insights from experimental models.

Authors:  G A Ferns; T Y Avades
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

Review 5.  The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.

Authors:  Felice Gragnano; Simona Sperlongano; Enrica Golia; Francesco Natale; Renatomaria Bianchi; Mario Crisci; Fabio Fimiani; Ivana Pariggiano; Vincenzo Diana; Andreina Carbone; Arturo Cesaro; Claudia Concilio; Giuseppe Limongelli; Mariagiovanna Russo; Paolo Calabrò
Journal:  Mediators Inflamm       Date:  2017-05-28       Impact factor: 4.711

Review 6.  Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.

Authors:  Nina Buchtele; Michael Schwameis; James C Gilbert; Christian Schörgenhofer; Bernd Jilma
Journal:  Thromb Haemost       Date:  2018-05-30       Impact factor: 5.249

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.